Stakeholders representing major gummy manufacturers, ingredient manufacturers, contract laboratories, and trade associations recently participated in a USP roundtable discussion on gummy dietary supplements. They shared their views on technical and quality challenges in manufacturing as well as scientific and public health considerations related to the future development of USP quality standards for gummy dietary supplements.
Anita Szajek, Ph.D., principal scientific liaison to USP’s Expert Panel on Therapeutic Peptides, examines therapeutic peptides, the transition from recombinant to synthetic manufacturing routes, and regulatory and quality-related questions.
Validation and verification of analytical procedures are quality assurance activities with broad impact in laboratory operations. Learn USP's role in the development of guidelines in these areas and how to contribute to the discussion.
Today, peptides represent one of the fastest growing segments in the pharmaceutical market. Hence, being able to manufacture peptides that are consistent in makeup and quality is an important priority for manufacturers of this drug class. This article discusses how the global pharmaceutical landscape continues to transform and how quality standards will play a growing role in the manufacture of these drugs.
